Evidence map›Paper›PMID 35247883›Full record

ReviewCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022

Cancer Epidemiology in Hispanic Populations: What Have We Learned and Where Do We Need to Make Progress?

Laura Fejerman, Amelie G Ramirez, Anna María Nápoles, Scarlett Lin Gomez, Mariana C Stern

Open access · bronzeAbstract readReview
In one paragraph

Review in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Lung Cancer Screening by Nativity Among Latino Community Health Center Patients.Journal of the American Board of Family Medicine : JABFM · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Access to care and the Hispanic paradox among Hispanic patients with hepatocellular carcinoma.Clinics and research in hepatology and gastroenterology · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Prostate Cancer Disparities in Clinical Characteristics and Survival among Black and Latino Patients Considering Nativity: Findings from the California Cancer Registry.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Laura FejermanDepartment of Public Health Sciences, UC Davis Comprehensive Cancer Center, University of California Davis, Davis, California.ORCID 0000-0003-3179-1151
Amelie G RamirezDepartment of Population Health Sciences, School of Medicine, Mays Cancer Center, The University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Anna María NápolesDivision of Intramural Research, National Institute on Minority Health and Health Disparities, NIH, Bethesda, Maryland.ORCID 0000-0001-8838-2899
Scarlett Lin GomezDepartment of Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Mariana C SternDepartment of Population and Public Health Sciences, Department of Urology, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.ORCID 0000-0001-9777-4683
National Institute on Minority Health and Health Disparities · USThe University of Texas Health Science Center at San Antonio · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of California, Davis · USUniversity of Southern California · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Institute for Integration of Medicine & Science: A Partnership to Improve HealthUM1TR004538 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ROBERT A CLARK, Kenneth M Hargreaves · 2023 to 2026
$22.3M
Tissue Modeling & Drug Development Shared Resources CoreU54CA233444 · NCI · UNIVERSITY OF FLORIDA · PI FERN Jureidini WEBB · 2018 to 2026
$12.1M
Tissue Modeling CoreU54CA233465 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JOYCE M RICHEY · 2018 to 2026
$11.9M
Translating Behavioral Interventions for Health Disparity PopulationsZIAMD000014 · NIMHD · NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES · PI CHOI, KELVIN · 2018 to 2023
$4.8M
Avanzando Caminos (Leading Pathways): The Hispanic/Latino Cancer Survivorship Cohort Study.”UG3CA260317 · NCI · UNIVERSITY OF MIAMI CORAL GABLES · PI PENEDO, FRANK J, RAMIREZ, AMELIE G · 2021 to 2022
$2.0M
Biological implications of breast cancer protective variants in Latin Americanwomen with high Indigenous American ancestryR01CA204797 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FEJERMAN, LAURA · 2016 to 2020
$1.9M
NCATS NIH HHS UM1 TR004538NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA054174NCI NIH HHS P30 CA082103NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA204797NCI NIH HHS U54 CA233444NCI NIH HHS U54 CA233465NCI NIH HHS UG3 CA260317
6 · The paper itself

Abstract

The Hispanic/Latino(x) population (H/L) in the United States of America is heterogeneous and fast growing. Cancer is the number one cause of death among H/Ls, accounting for 21% of deaths. Whereas for the most common cancers, incidence rates are lower in H/Ls compared with non-H/L White (NHW) individuals, H/Ls have a higher incidence of liver, stomach, cervical, penile, and gallbladder cancers. H/L patients tend to be diagnosed at more advanced stages for breast, colorectal, prostate, and lung cancers, and melanoma compared with NHW individuals. Etiologic and cancer outcomes research among H/Ls lags other populations. In this review, we provide a summary of challenges, opportunities, and research priorities related to cancer etiology, cancer outcomes, and survivorship to make progress in addressing scientific gaps. Briefly, we prioritize the need for more research on determinants of obesity, nonalcoholic fatty liver disease and its progression to liver cancer, stomach and gallbladder cancers, and pediatric acute lymphoblastic leukemia. We emphasize the need to improve cancer screening, early detection of cancer, and survivorship care. We highlight critical resources needed to make progress in cancer epidemiologic studies among H/L populations, including the importance of training the next generation of cancer epidemiologists conducting research in H/Ls.

Indexed as

Gallbladder NeoplasmsLiver NeoplasmsMelanomaNeoplasmsChildHispanic or LatinoHumansIncidenceMaleSurvivorshipUnited States

Identifiers

PMID35247883
PMCPMC9081152
OpenAlexW4220678535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.